key: cord-1022127-9rr0qo16 authors: Appelbaum, Jacob; Arnold, Donald M; Kelton, John G; Gernsheimer, Terry; Jevtic, Stefan D; Ivetic, Nikola; Smith, James W; Nazy, Ishac title: SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia date: 2021-11-03 journal: Blood Adv DOI: 10.1182/bloodadvances.2021005050 sha: 5b5d5ac1d0c4a90fe804c6fa5582baba4a7c7d89 doc_id: 1022127 cord_uid: 9rr0qo16 nan Coronavirus disease 2019 (COVID-19) is a severe viral illness that has resulted in significant morbidity and mortality worldwide. Several vaccines have been created that can prevent disease transmission, as well as severity and mortality. All COVID-19 vaccines use the SARS-CoV-2 Spike protein as the antigenic substrate. However, serious adverse reactions have been reported, including more than 150 cases of thrombocytopenia following vaccination 1 . A precise mechanism linking COVID-19 vaccination and severe thrombocytopenia has yet to be confirmed. Identifying this mechanism could facilitate diagnostic test development. The serotonin release assay (SRA) is the gold-standard diagnostic test for heparin-induced thrombocytopenia 2 , which is characterized by severe thrombocytopenia and a high risk of thrombosis. Using the SRA, we recently showed that a subset of critically ill COVID-19 patients test positive for platelet-activating immune complexes 3 Anti-PF4/heparin antibody testing was done using an anti-PF4/heparin enzymatic immunoassay (EIA, LIFECODES PF4 enhanced assay, Immucor GTI Diagnostics, Waukesha, Wisconsin) for IgG, IgM, and IgA PF4/heparin antibodies. Standard SRA testing was conducted in the absence and presence of heparin (0.1, 0.3, and 100 U/mL) or with exogenous PF4 added as previously 4 described 2,5,6 . A modified SRA (Spike-SRA) was performed through exogenous administration of SARS-CoV-2 Spike protein at varying concentrations (0, 0.5, 5, 50, 100 µg/mL). Testing was also completed with varying amounts of Moderna vaccine or polyethylene glycol (PEG2000). Anti-human CD32 antibody (IV.3) or intravenous immunoglobulin (IVIg) was added to the SRA to confirm FcγRIIA signalling. Platelet autoantibody binding was completed using washed donor platelets and tested using flow cytometry, platelet glycoprotein-specific enzyme immunoassay (PakPlus, Immucor), and radioimmunoprecipitation assay, as previously described 7, 8 . Our patient was a 25-year-old woman who presented to hospital ten days after receiving the Moderna mRNA COVID-19 vaccine with fatigue, petechiae and wet purpura. The initial platelet count was 1,000 per cubic millimeter without evidence of schistocytes on blood smear. Anti-platelet factor 4 (PF4)/heparin antibodies were not detected (OD = 0.221) and the classic SRA test, with or without heparin or exogenous PF4, was negative. Assays for drug-induced immune thrombocytopenia with washed donor platelets were also negative for platelet binding with vaccine, PEG2000, or SARS-CoV-2 Spike protein; assays included flow cytometry, platelet glycoprotein-specific enzyme immunoassay, and radioimmunoprecipitation. 3 These results support an alternative diagnosis to drug-induced immune thrombocytopenia, although it cannot be fully excluded. The patient was treated with dexamethasone and intravenous immune globulin (IVIg) for a presumed immune thrombocytopenic purpura. The platelet count normalized by day seven of treatment ( Figure 1A ). Together, these results suggest that the thrombocytopenia in this patient was secondary to FcγRIIa-mediated platelet activation by SARS-CoV-2 Spike immune complexes. Our serological investigations highlight a potential mechanism for COVID-19 VIT involving SARS-CoV-2 Spike-dependent, FcγRIIa-mediated platelet activation. Similar immune complex mediated platelet activation has also been observed with severe COVID-19 infection. 2, 4 The mechanism described here resembles platelet activation seen in HIT but does not involve anti-PF4/heparin antibodies. While HIT serves as a useful analogy, certain key differences are noted 6 in our case. Notably, the patient presented with bleeding symptoms as opposed to thrombosis; however, in parallel to HIT, not all patients with platelet-activating antibodies develop thrombosis 10 . Finally, it is unclear why only a minority of patients with anti-Spike antibodies feature such thrombocytopenia and platelet activation. One hypothesis is that platelet activation is dependent on unique Spike protein epitopes, which are only recognized by a minority of identified antibodies, as seen in HIT 11 . Therefore, using our knowledge of platelet activation from studying HIT, we propose this mechanism for COVID-19 VIT involving SARS-CoV-2 anti-Spike antibodies. It is important to recognize that the mechanism described here is unique from the recently reported HIT-like syndrome associated with AstraZeneca vaccination 12 . In this syndrome, patients present with life-threatening thrombosis in the context of strongly positive, platelet activating anti-PF4/heparin antibodies. The mechanism of VIT proposed here is independent of anti-PF4/heparin antibodies and presents differently. Our case also highlights the applicability of the SRA to detect platelet activation disorders aside from HIT. Although classically done in the presence of heparin, it can be modified to include various antigens to elicit immune complex formation and identify platelet activation. In our case, addition of Spike protein led to significant platelet activation that was inhibited by IV.3 and IVIg, suggesting immune complex signalling. The SRA may thus prove useful in a variety of other clinical scenarios involving platelet activation, as has been shown here. Ultimately, the role of SARS-CoV-2 Spike protein requires further clarification in regards to platelet activation, as well as the role of vaccine-and PEG-dependent platelet activation. We postulate that a small subset of antibodies against the Spike protein, formed after vaccination, can activate platelets and cause thrombocytopenia. The prevalence of this phenomenon remains 7 to be clinically determined. Regardless, the modified SRA presented here may be a useful diagnostic test as more cases of vaccine-induced thrombocytopenia are recognized. 8 For data sharing, contact the corresponding author: nazyi@mcmaster.ca. The platelet count fully recovered by day 7 of treatment with dexamethasone and intravenous immunoglobulin (IVIg). Serum from the patient (black squares) caused dose-dependent platelet activation and serotonin release with spike protein (93%, 100 µg/mL) and with vaccine (53%, 50 µL/mL). This effect was not observed with plasma from recovered COVID-19 subjects with severe (n=5, black circles) or mild infection (n=3, white circles). The activation was inhibited with FcγRIIa blockade using the monoclonal antibody IV.3 (5 µg/mL) or IVIg (400 µg/mL). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination A diagnostic test for heparin-induced thrombocytopenia Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia Antibody-induced procoagulant platelets in severe COVID-19 infection Distinguishing between antiplatelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH A systematic evaluation of laboratory testing for druginduced immune thrombocytopenia Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects A 14-year study of heparin-induced thrombocytopenia Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination The All authors reviewed and approved the final version of the manuscript. The authors declare no competing financial interests.